Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-IL1RAP antibody
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-IL1RAP antibodies are a class of biologic therapeutics designed to target the Interleukin-1 Receptor Accessory Protein (IL1RAP, also known as IL1R3). IL1RAP is a critical co-receptor for multiple pro-inflammatory cytokine subfamilies, including IL-1, IL-33, and IL-36, making it a central node in inflammatory signaling. By blocking IL1RAP, these antibodies can simultaneously inhibit multiple signaling pathways involved in cancer progression and autoimmune diseases. In oncology, IL1RAP is often overexpressed on cancer cells and leukemic stem cells (LSCs), and its inhibition can trigger antibody-dependent cellular cytotoxicity (ADCC) or block growth-promoting signals. Several companies are developing candidates in this space, including Cantargia (nadunolimab, CAN10), Singlomics (DXP-006, DXP-106), and Cellerant Therapeutics.
- Other names
- anti-IL1R3 antibodyanti-IL-1R3 antibodyanti-IL 1R3 antibodyIL1RAP antibodyIL-1RAP antibodyIL 1RAP antibody
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on anti-IL1RAP antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-IL1RAP antibody.